Clinical Pharmacology of LT5001 Drug Product in Hemodialysis Patients With Uremic Pruritus to Assess the Safety, Local Tolerance and Pharmacokinetics
Latest Information Update: 05 May 2022
At a glance
- Drugs LT 5001 (Primary)
- Indications Pruritus
- Focus Adverse reactions
- Sponsors Lumosa Therapeutics
Most Recent Events
- 20 May 2020 New trial record